NCT03125655

Brief Summary

Psoriasis is a chronic and recurrent skin disorder characterized by marked inflammatory changes in the skin. An extensive cytokine network including generated by activated dendritic cells and T cells mediates the formation of psoriatic lesions. These immune-response parameters can be used as markers in the severity and management of the disease after further in-depth studies.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
13

participants targeted

Target at below P25 for all trials

Timeline
11mo left

Started Apr 2014

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Apr 2014Apr 2027

Study Start

First participant enrolled

April 22, 2014

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

April 17, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

April 24, 2017

Completed
9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 10, 2026

Completed
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

April 28, 2027

Expected
Last Updated

March 27, 2025

Status Verified

March 1, 2024

Enrollment Period

12 years

First QC Date

April 17, 2017

Last Update Submit

March 24, 2025

Conditions

PsoriasisInflammation

Keywords

cytokines

Outcome Measures

Primary Outcomes (1)

  • Inflammatory genes

    TNF-alpha , IFN-alpha , IL-6, IL-8, IL-12 , IL-23, IL-4, IL-5 and IL-10

    1 day

Interventions

Inflammatory markersDIAGNOSTIC_TEST

Eligibility Criteria

Age19 Years - 99 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Subjects 19 and older will be recruited from the Dermatology clinics at UAB

You may qualify if:

  • Clinical diagnosis of psoriasis
  • Must be age 19 or older.
  • Must be Fitzpatrick skin type I, II, III, IV, V, VI.

You may not qualify if:

  • Subjects who do not have photosensitive disease and are not on photosensitizing medications.
  • Subjects with a history of keloids (who are more likely to develop hypertrophic scars following skin biopsy).
  • Subjects who have an allergy to local anesthetics, antibiotics and/or anticoagulants.
  • Subjects who are pregnant.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Kirklin Clinic

Birmingham, Alabama, 35294, United States

RECRUITING

MeSH Terms

Conditions

PsoriasisInflammation

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

April 17, 2017

First Posted

April 24, 2017

Study Start

April 22, 2014

Primary Completion

April 10, 2026

Study Completion (Estimated)

April 28, 2027

Last Updated

March 27, 2025

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations

US(1)